Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 23% ± 9% | |
smooth muscle cell | 7 studies | 23% ± 6% | |
GABAergic neuron | 7 studies | 38% ± 21% | |
fibroblast | 7 studies | 21% ± 5% | |
glutamatergic neuron | 6 studies | 45% ± 25% | |
interneuron | 6 studies | 36% ± 23% | |
ciliated cell | 6 studies | 28% ± 13% | |
epithelial cell | 5 studies | 27% ± 8% | |
cardiac muscle cell | 5 studies | 41% ± 12% | |
astrocyte | 5 studies | 33% ± 15% | |
neuron | 4 studies | 35% ± 18% | |
retinal cone cell | 4 studies | 35% ± 11% | |
retinal rod cell | 4 studies | 25% ± 8% | |
oligodendrocyte precursor cell | 4 studies | 28% ± 7% | |
pericyte | 4 studies | 28% ± 7% | |
GABAergic interneuron | 3 studies | 19% ± 2% | |
endothelial cell of lymphatic vessel | 3 studies | 17% ± 1% | |
lymphocyte | 3 studies | 19% ± 2% | |
transit amplifying cell | 3 studies | 29% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 805.81 | 1445 / 1445 | 100% | 16.44 | 183 / 183 |
ovary | 100% | 590.74 | 180 / 180 | 100% | 11.32 | 430 / 430 |
prostate | 100% | 660.76 | 245 / 245 | 100% | 18.12 | 502 / 502 |
lung | 100% | 641.30 | 577 / 578 | 100% | 12.87 | 1155 / 1155 |
intestine | 100% | 731.76 | 966 / 966 | 100% | 10.02 | 526 / 527 |
breast | 100% | 488.13 | 459 / 459 | 100% | 10.79 | 1113 / 1118 |
uterus | 100% | 821.38 | 170 / 170 | 99% | 10.47 | 456 / 459 |
stomach | 100% | 439.05 | 359 / 359 | 99% | 11.09 | 284 / 286 |
bladder | 100% | 602.71 | 21 / 21 | 99% | 10.17 | 500 / 504 |
thymus | 100% | 933.25 | 653 / 653 | 99% | 8.73 | 600 / 605 |
pancreas | 100% | 448.49 | 328 / 328 | 99% | 9.33 | 176 / 178 |
brain | 98% | 381.41 | 2585 / 2642 | 100% | 7.18 | 702 / 705 |
kidney | 100% | 489.04 | 89 / 89 | 96% | 7.59 | 866 / 901 |
adrenal gland | 100% | 592.36 | 258 / 258 | 95% | 6.92 | 219 / 230 |
liver | 100% | 448.91 | 226 / 226 | 94% | 5.37 | 380 / 406 |
skin | 100% | 751.30 | 1808 / 1809 | 92% | 7.29 | 435 / 472 |
blood vessel | 100% | 923.35 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 486.45 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.88 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.37 | 1 / 1 |
adipose | 100% | 492.30 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 771.10 | 848 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 344.54 | 779 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 5.07 | 27 / 29 |
peripheral blood | 76% | 315.34 | 710 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 59% | 2.39 | 47 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006654 | Biological process | phosphatidic acid biosynthetic process |
GO_0036149 | Biological process | phosphatidylinositol acyl-chain remodeling |
GO_0035965 | Biological process | cardiolipin acyl-chain remodeling |
GO_0016024 | Biological process | CDP-diacylglycerol biosynthetic process |
GO_0012505 | Cellular component | endomembrane system |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0003841 | Molecular function | 1-acylglycerol-3-phosphate O-acyltransferase activity |
GO_0008374 | Molecular function | O-acyltransferase activity |
GO_0016746 | Molecular function | acyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | LCLAT1 |
Protein name | Lysocardiolipin acyltransferase 1 Lysocardiolipin acyltransferase 1 (EC 2.3.1.-) (1-acylglycerol-3-phosphate O-acyltransferase 8) (1-AGP acyltransferase 8) (1-AGPAT 8) (EC 2.3.1.51) (Acyl-CoA:lysocardiolipin acyltransferase 1) |
Synonyms | AGPAT8 LYCAT ALCAT1 UNQ1849/PRO3579 |
Description | FUNCTION: Exhibits acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity; catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling (By similarity). Recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors (By similarity). Also exhibits 1-acyl-sn-glycerol-3-phosphate acyltransferase activity (AGPAT) activity; converts 1-acyl-sn-glycerol-3- phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3- phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone . Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities . Required for establishment of the hematopoietic and endothelial lineages (By similarity). . |
Accessions | ENST00000379509.8 [Q6UWP7-3] C9JXY8 ENST00000466477.5 C9JA02 Q6UWP7 C9J5S5 ENST00000476038.5 ENST00000488144.5 ENST00000497423.1 C9K0C3 C9J6F4 ENST00000465200.5 C9JUV9 F8WEY2 C9JMW2 ENST00000309052.8 [Q6UWP7-1] ENST00000478015.5 ENST00000319406.8 [Q6UWP7-2] ENST00000465538.5 ENST00000476535.1 |